Based on Zealand’s leading expertise in peptide drug innovation and development, we have built a strong franchise in the field of novel peptide drugs targeting better treatment of patients with metabolic disorders. Currently, our drug pipeline comprises three Zealand invented peptide agonists in clinical development for the treatment of diabetes and obesity, all of which are covered by partnership agreements with two of the worlds leading diabetes companies, Sanofi and Boehringer Ingelheim, respectively;
- Lyxumia®, a novel once-daily GLP-1 agonist, in registration phase in Europe as a novel treatment for Type 2 diabetes under license partnership with Sanofi.
- Lyxumia®/Lantus®, a GLP-1 basal insulin combination product in preparation for Phase III development as a novel treatment option for patients with Type 2 under licence partnership with Sanofi.
- ZP2929, a novel dual acting glucagon/GLP-1 agonist, in clinical Phase I under partnership with Boehringer Ingelheim.